Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hormone Refractory Prostate Cancer 1

Interventions

Cyclophosphamide 166 Docetaxel 154 Bevacizumab 153 Carboplatin 148 Gemcitabine 146 Cisplatin 146 pembrolizumab 144 Radiotherapy 135 Paclitaxel 132 Capecitabine 122 Rituximab 115 Oxaliplatin 104 Fluorouracil 103 Nivolumab 94 Irinotecan 85 Doxorubicin 85 Pemetrexed 83 Leucovorin 82 Dexamethasone 82 fludarabine 74 fludarabine phosphate 72 Bortezomib 69 Etoposide 67 Erlotinib Hydrochloride 66 Cetuximab 65 Methotrexate 58 Trastuzumab 56 Cytarabine 54 Lenalidomide 50 Everolimus 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × Mycobacterium w vaccine × Clear all

NCT00525408 2012-03-12

HRPC

Cadila Pharnmaceuticals

Phase 2 Terminated

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡